Treatment for Age - Related Macular Degeneration (AMD)

Phase-Based Progress Estimates
John Hopkins University Hospital, Baltimore, MD
Age - Related Macular Degeneration (AMD)+1 More
All Sexes
Eligible conditions

Study Summary

This study is evaluating whether a gene transfer agent is safe for people with age-related macular degeneration.

See full description

Eligible Conditions

  • Age - Related Macular Degeneration (AMD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Age - Related Macular Degeneration (AMD)

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 1 secondary outcome in patients with Age - Related Macular Degeneration (AMD). Measurement will happen over the course of 15 years.

15 years
The change from baseline in BCVA.
The incidence of adverse events

Trial Safety

Safety Progress

1 of 3

Other trials for Age - Related Macular Degeneration (AMD)

Trial Design

0 Treatment Group

This trial requires 18 total participants across 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 15 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 15 years for reporting.

Closest Location

John Hopkins University Hospital - Baltimore, MD

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Must have received a subretinal injection of RetinoStat
Must have been enrolled in Protocol RS1/001/10

Patient Q&A Section

What are the signs of macular degeneration?

"Macular degeneration is diagnosed and confirmed by two or more signs.\n\nthe three most common signs are visual field impairment or decreased central vision (25%), colour blindness (20%), and blurred vision (20%).\n\nAdditional signs of macular degeneration:\n\n1. Photopsia: vision changes that may or may not be associated with pain.\n2. Retinal pigment neovascular changes may appear in the form of telangiectasia, telesias, or drusen.\n3. Micro-blot haemorrhages may also be seen along the centre-sulcus." - Anonymous Online Contributor

Unverified Answer

What are common treatments for macular degeneration?

"Vitamins A and E and high levels of zinc are important for people with [macular degeneration](, regardless of age. Vitamins A, D, E and zinc are all found in milk, and the benefits of high vitamin D levels to prevent or slow vision loss are more widely recognized than those of zinc which has been a mystery until now. The evidence shows that zinc supplementation at low doses does have an effect on visual acuity or macular sensitivity improvement, but not change in visual function. Higher doses can be harmful." - Anonymous Online Contributor

Unverified Answer

What causes macular degeneration?

"Results from a recent paper support the hypothesis that elevated blood homocysteine concentrations cause macular degeneration and that macular degeneration is a risk factor for elevated homocysteine." - Anonymous Online Contributor

Unverified Answer

Can macular degeneration be cured?

"It is extremely unlikely to halt, reverse, or delay AMD and only in very rare instances might a therapy of some sort be able to halt the progression of the disease. Data from a recent study of the ASCRS are not so surprising, because the ASCRS only reported on vision tests. In order to prevent AMD, it takes preventive measures as well as therapeutic ones. If it is not good enough with either, the end of the world cannot be reached, since it can only prevent the disease from occurring at all. However, I am still very hopeful and happy that therapies are being perfected and are soon to be available to stop AMD from progressing." - Anonymous Online Contributor

Unverified Answer

How many people get macular degeneration a year in the United States?

"Data from a recent study from this study suggest that about 3% of the US population has some degree of AMD-related visual impairment and that over 250,000 adults need specialized vision health services annually. This estimate indicates that the total burden imposed by macular degeneration and its related vision loss has not yet been recognized to the extent of other diseases." - Anonymous Online Contributor

Unverified Answer

What is macular degeneration?

"Macular degeneration is a degenerative eye disease characterised by loss of central vision. These patients may also be at an increased risk for developing age-related macular degeneration and, in turn, ocular diseases. In some cases, they develop choroidal neovascular membrane. The cause of macular degeneration remains unclear. It is a multifactorial condition caused most likely by a combination of genetics, aging, and environmental risk factors or risk factors. Macular Degeneration should be treated in such a way that prevents further progressive loss of vision and improves the patient's quality of life." - Anonymous Online Contributor

Unverified Answer

What does treatment usually treat?

"There is no clear definition as to what treatment does or does not work. Treatment is complicated by the variety of conditions which can appear clinically similar, and also by the difficulty of distinguishing between them and the variability of the progression of a condition from one diagnosis to another. Treatment, once started, must be followed for a long time, often for many years, because many treatments do not always stop vision loss from occurring. In addition, there is no standardisation of the management of any type of condition, which can lead to variability and difficulties in follow-up and treatment monitoring." - Anonymous Online Contributor

Unverified Answer

What is the latest research for macular degeneration?

"Since an increase in the discovery of MD in the past decade, it is more evident the need for new treatment as well as new diagnostics for this kind of eye disease. A good overview of all the new advances in the medical treatment for [macular degeneration]( is provided in Table 1. As reported over the last years, the research focuses more on clinical trials rather than basic and pre-clinical research, with only a very limited percentage provided on safety, efficacy and tolerability. Considering all these parameters combined into a balanced research agenda, a long and more coherent and controlled clinical trial is needed." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating macular degeneration?

"The most obvious, but most risky, option is the one based on surgery. All known modes of therapy are surgical. But there is not a whole lot to say either about a new or a more effective surgical operation that may possibly be developed in the future." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of macular degeneration?

"Findings from a recent study suggest that other factors may be more important for the progression of macular degeneration than the number of eye autofluorescence intensities. The number of eye autofluorescence intensities may reflect the time-average intensity of circulating AGEs in the bloodstream. This approach may allow monitoring the risk of macular degeneration in an effective way." - Anonymous Online Contributor

Unverified Answer

Is treatment typically used in combination with any other treatments?

"Treatments for dry macular degeneration are usually prescribed with an eye medication. In the majority of patients, the eye drops are the sole treatment needed for dry macular degeneration. There are instances when patients use medication and/or surgery as a supplement that is needed in combination with other treatments for dry macular degeneration." - Anonymous Online Contributor

Unverified Answer

Does macular degeneration run in families?

"This is a large-scale, prospective family study confirming the high and moderate heritability of macular degeneration of the advanced type. In addition to studies on the heritability of myopia, this is another report showing that this disease is a complex disorder of multifactorial origin with possible influence of environmental risk factors. This has important implication for the public perception of macular degeneration. The fact that family aggregation seems to point to an autosomal dominant inheritance, and the very high and significant heritability of myopia in this study makes it clear that the determination of genetic predisposition to the disease in general is essential for understanding this disease and to obtain effective preventive measures." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Age - Related Macular Degeneration (AMD) by sharing your contact details with the study coordinator.